Equities research analysts predict that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will announce $80,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cardiff Oncology’s earnings, with estimates ranging from $50,000.00 to $100,000.00. Cardiff Oncology posted sales of $70,000.00 during the same quarter last year, which suggests […]
Related Keywords
Robertw Baird , William Blair , Cardiff Oncology Inc , Elkhorn Partners Limited Partnership , Zacks Investment Research , Manufacturers Life Insurance Company , Nasdaq , Invesco Ltd , Cardiff Oncology Company Profile Get Rating , Maxim Group , Citigroup Inc , Cardiff Oncology , Get Rating , Investment Research , Partners Limited Partnership , Oncology Company Profile , Polo Like Kinase , Nasdaq Crdf , Acrdf , Medical , Ratings , Consensus ,
comparemela.com © 2020. All Rights Reserved.